Late-Onset Neutropenia Common in Patients on Rituximab Late-Onset Neutropenia Common in Patients on Rituximab
"Even though most [cases] are incidental and can be self-limiting, some can be severe and associated with sepsis."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Lower Rituximab Dose as Effective, Safer in MS Lower Rituximab Dose as Effective, Safer in MS
Further data suggest that a lower dose of rituximab may offer similar effectiveness with a better safety profile than a higher dose commonly used.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 18, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Disseminated Enterovirus Infection With Rituximab/Ibrutinib Disseminated Enterovirus Infection With Rituximab/Ibrutinib
This case underscores the risk for severe and potentially life-threatening immune-related side effects with combined therapy with rituximab and ibrutinib.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab In MS, Serious AEs More Common in Rituximab vs Ocrelizumab
Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Lowering Rituximab Dose in Patients With MS Safe, Effective Lowering Rituximab Dose in Patients With MS Safe, Effective
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and stable choice for patients with multiple sclerosis.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 10, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

RA Infection Risk With Abatacept, Rituximab and Tocilizumab RA Infection Risk With Abatacept, Rituximab and Tocilizumab
How common are infections among rheumatoid arthritis patients receiving treatment with these non-TNF-inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Binding mechanisms of therapeutic antibodies to human CD20
Monoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differentiation 20) constitute important immunotherapies for the treatment of B cell malignancies and autoimmune diseases. Type I and II therapeutic mAbs differ in B cell binding properties and cytotoxic effects, reflecting differential interaction mechanisms with CD20. Here we present 3.7- to 4.7-angstrom cryo–electron microscopy structures of full-length CD20 in complexes with prototypical type I rituximab and ofatumumab and type II obinutuzumab. The structures and binding thermodynamics demonstrate that upon binding to CD20, type II mAbs form te...
Source: ScienceNOW - August 13, 2020 Category: Science Authors: Kumar, A., Planchais, C., Fronzes, R., Mouquet, H., Reyes, N. Tags: Biochemistry, Medicine, Diseases r-articles Source Type: news

Cladribine With Concurrent or Delayed Rituximab in HCL Cladribine With Concurrent or Delayed Rituximab in HCL
Could the addition of rituximab to cladribine treatment help clear minimal residual disease in patients with hairy cell leukemia?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Isolated IgG4-Related Hypophysitis Treated With Rituximab Isolated IgG4-Related Hypophysitis Treated With Rituximab
Is rituximab a safe and effective treatment option for IgG4-related hypophysitis?Journal of the Endocrine Society (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 30, 2020 Category: Intensive Care Tags: Diabetes & Endocrinology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche collaborates with Blueprint Medicines to bring a new treatment to people with RET-altered cancers
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Roche Pharma India expands partnership with Cipla for key oncology medicines
Roche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India," the company said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 18, 2020 Category: Pharmaceuticals Source Type: news

Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
THURSDAY, June 4, 2020 -- For children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin lymphoma, rituximab added to standard lymphomes malins B (LMB) chemotherapy prolongs event-free survival, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Phase III results show rituximab excels against pediatric Burkitt lymphoma
(University of Colorado Anschutz Medical Campus) Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2020 Category: International Medicine & Public Health Source Type: news

Long-Term Rituximab May Aid in Antibody-Associated Vasculitis
TUESDAY, June 2, 2020 -- For patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), extended therapy with rituximab is associated with a reduced incidence of antineutrophil cytoplasmic antibody-associated vasculitis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2020 Category: Pharmaceuticals Source Type: news

Rituximab Promising in New-Onset Myasthenia Gravis Rituximab Promising in New-Onset Myasthenia Gravis
New research suggests rituximab is safer and more effective than immunosuppressants for myasthenia gravis, especially in new-onset disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab Offers No Extra Benefit to Induction Chemo in ALL Rituximab Offers No Extra Benefit to Induction Chemo in ALL
Patients with B-precursor acute lymphoblastic lymphoma may not benefit from adding rituximab to standard induction chemotherapy, suggests UK trial data that also identified novel genetic risk factors.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

E1912 trial leads to FDA approval of ibrutinib-rituximab combo for untreated CLL
(ECOG-ACRIN Cancer Research Group) Patients aged 70 or younger with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma have a new treatment option -- a combination of the targeted agent ibrutinib with the immunologic agent rituximab. The FDA has approved the combination based on data from E1912, a phase 3 trial that showed this combination provides better leukemia control, prolongs life, and has fewer side effects compared to standard care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2020 Category: Cancer & Oncology Source Type: news

Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA ® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
HORSHAM, PA, April 24, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate. If approved for these indications, SIMPONI ARIA would be the first anti-tumor necrosis factor (TNF)-alpha biologic agent administered by intravenous infusion av...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Ibrutinib Plus Rituximab Combo for CLL FDA Approves Ibrutinib Plus Rituximab Combo for CLL
This combination of targeted agents showed better progression-free survival than a standard chemoimmunotherapy regimen in patients with newly diagnosed chronic lymphocytic leukemia.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
HORSHAM, Pa., April 21, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of IMBRUVICA® (ibrutinib) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are new to therapy. The approval is based on positive results from the landmark Phase 3 E1912 study that was designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute, part of the National Institutes of Health. Today’s mi...
Source: Johnson and Johnson - April 22, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Ibrutinib Combined with Rituximab for Patients with CLL/SLL
The FDA approved ibrutinib in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - April 22, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Imbruvica (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
NORTH CHICAGO, Ill., April 21, 2020– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved the use of Imbruvica® (ibrutinib) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 21, 2020 Category: Drugs & Pharmacology Source Type: news

Rituximab for Maintenance of Remission in ANCA Vasculitis Rituximab for Maintenance of Remission in ANCA Vasculitis
This article provides a summary of new guidelines regarding the use of rituximab as a treatment option in remission maintenance of ANCA-associated vasculitis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 17, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Russian antitumor drugs first time registered in Europe
(BIOCAD) Two BIOCAD products, Acellbia (INN: rituximab) and Herticad (INN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina. Registration was received with the support of ICM d.o.o partner and is valid for 5 years. The first deliveries shall start in June 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2020 Category: Cancer & Oncology Source Type: news

Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Patients and RWE: Is this the year?
The long-hyped redefinition of healthcare through wearable tech has been … well, long hyped. Early projects, such as Apple HealthKit and Fitbit, were undoubtably important in redefining ‘the possible’ but they haven’t yet achieved transformative application.  Much has been written on why the philosophy that has driven the astonishing success of consumer technology doesn ’t translate to healthcare and when we look at the state of innovation in 2020, many of these structural issues remain.   As Emily Cerciello, Associate Director, Digital Health and Engagement at the Crohn's...
Source: EyeForPharma - March 26, 2020 Category: Pharmaceuticals Authors: Tom Disley Source Type: news

Relapse With Rituximab More Common in Severe Pemphigus Relapse With Rituximab More Common in Severe Pemphigus
Pemphigus patients with severe disease and those with persistent anti-desmoglein (DSG) antibodies three months after starting treatment with rituximab are more prone to relapse while on the drug, according to a new post hoc analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2020 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
FDA approves Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children ages 2 and older in combination with steroid hormones. It is the first approved treatment for children with these rare vasculitis diseases. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Investor Update - March 23, 2020 Category: Pharmaceuticals Source Type: news

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia
Basel, 23 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate (CR + CRi). Venclexta ®/Venclyxto® (venetoclax) in combination with azacitidine, a hypomethylating agent, showed a statistically significant improvement in overall survival in people with previously untreated acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy, compared to azacitidine alone. Safety for Venclexta/Venclyxto plus azacitidine appeared consistent with the known safety profile ...
Source: Roche Media News - March 23, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development...
Source: Roche Media News - March 12, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
Basel, 12 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).“Venclyxto plus Gazyvaro is the first fixed-duration, chemotherapy-free treatment option that has been shown to help patients with untreated chronic lymphocytic leukaemia live longer without their disease progressing,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development...
Source: Roche Investor Update - March 12, 2020 Category: Pharmaceuticals Source Type: news

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Cluster of differentiation 20 (CD20) is a B cell membrane protein that is targeted by monoclonal antibodies for the treatment of malignancies and autoimmune disorders but whose structure and function are unknown. Rituximab (RTX) has been in clinical use for two decades, but how it activates complement to kill B cells remains poorly understood. We obtained a structure of CD20 in complex with RTX, revealing CD20 as a compact double-barrel dimer bound by two RTX antigen-binding fragments (Fabs), each of which engages a composite epitope and an extensive homotypic Fab:Fab interface. Our data suggest that RTX cross-links CD20 i...
Source: ScienceNOW - March 12, 2020 Category: Science Authors: Rouge, L., Chiang, N., Steffek, M., Kugel, C., Croll, T. I., Tam, C., Estevez, A., Arthur, C. P., Koth, C. M., Ciferri, C., Kraft, E., Payandeh, J., Nakamura, G., Koerber, J. T., Rohou, A. Tags: Biochemistry, Immunology r-articles Source Type: news

Rituximab with BEAM Conditioning Prior to Auto-HCT for DLBCL not Recommended
This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Media News - February 25, 2020 Category: Pharmaceuticals Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the European Commission has granted conditional marketing authorisation for Polivy ® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - January 21, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the European Commission has granted conditional marketing authorisation for Polivy ® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - January 21, 2020 Category: Pharmaceuticals Source Type: news

Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCL
Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Diego Villa, MD, FRCPC Source Type: news

Truxima (Rituximab-abbs Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 2, 2020 Category: Drugs & Pharmacology Source Type: news

Switching From Rituximab to Biosimilar CT-P10 in RA Switching From Rituximab to Biosimilar CT-P10 in RA
CT-P10, a biosimilar of reference rituximab, may be a safe and effective treatment option for patients with rheumatoid arthritis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan ® (rituximab)
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA. (Source: World Pharma News)
Source: World Pharma News - December 19, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

John M. Pagel, MD, PhD, on Polatuzumab Vedotin
The Swedish Cancer Center expert discussed the addition of polatuzumab vedotin to a bendamustine-rituximab regimen at the ASH Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2019 Category: Cancer & Oncology Authors: John M. Pagel, MD, PhD Source Type: news

IMBRUVICA ® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were m aintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA® · IMBRUVICA® plus ven e...
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL
The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news